GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-03-31| Licensing

GSK Bets $593 Million To License Scynexis’ Oral Antifungal

by Joy Lin
Share To

Drug giant GlaxoSmithKline (GSK) is licensing Scynexis’ Brexafemme (ibrexafungerp tablets) in a deal valued at nearly $600 million. 

Brexafemme is the first oral antifungal to be approved by the US FDA for the treatment of vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent VVC (RVVC). VVC is a common yeast infection of the vagina, affecting up to 75% of women at least once, while 40-45% may experience two or more episodes. 

Related Article: Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact

Brexafemme Adds To GSK’s Antibiotic Portfolio

The exclusive license gives GSK the right to market Brexafemme for its two approved indications while also developing the antifungal, which is undergoing Phase 3 trials in invasive candidiasis (IC), a life-threatening fungal infection. The license covers all countries with the exception of the greater China region and countries where Brexafemme is already out-licensed. 

Under the terms of the agreement, Scynexis will receive $90 million upfront and up to $503 million in milestone payments. $245.5 million will be paid upon achieving development, regulatory, and commercial milestones related to the IC indication. The company could earn an extra $15 million if the FDA approves an additional indication. Commercial sales of Brexafemme could net Scynexis milestones payments of up to $242.5 million, along with tiered royalties in the mid-single digits to mid-teens. 

According to GSK, Brexafemme will complement the company’s portfolio, which includes gepotidacin, a late-stage antibiotic for uncomplicated urinary tract infection (uUTI), and tebipenem, gepotidacin’s counterpart for complicated cases of UTI (cUTI). 

“The challenge of antimicrobial resistance includes increasing rates of multi-drug resistant fungal infections. Brexafemme is a novel, approved antifungal medicine with a broad spectrum of activity against existing and emerging resistant strains of fungi. In addition, the transaction consolidates GSK’s synergistic portfolio of innovative late-stage antibiotics,” said Luke Miels, Chief Commercial Officer, GSK. 

Invasive candidiasis is an infection caused by a yeast called Candida. It can affect the tissues such as the blood, heart, brain, and other parts around the body. Multidrug-resistant types of Candida, such as Candida auris, is an emerging threat to the global healthcare system. According to the Centers for Disease Control and Prevention (CDC), C. auris infections in the US nearly doubled in 2021, from 756 to 1,471 cases. Nationwide, there were 2,377 clinical cases in 2022. The majority of cases were found to be resistant to antifungal treatments such as azoles, polyenes, and echinocandins. 

Brexafemme, a glucan synthase inhibitor, could provide an additional line of offense against antimicrobial resistance with its distinct mechanism of action, which is similar to echinocandins. The agent has shown activity against C. auris and C. albicans, two WHO-designated priority fungal pathogens

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
GSK Secures Approval From Chinese NMPA for Nucala, its Add-On-Therapy to Treat CRSwNP
2025-01-07
GSK Expands Arexvy Approval to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
2024-12-02
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top